Back to first-pass browser

First-pass extracted concept

FAM168B

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

family with sequence similarity 168 member B, MANI, myelin-associated neurite-outgrowth inhibitor

Extracted Explainers

What the tool is doing

FAM168B is presented as a membrane-associated protein expressed on cancer cell surfaces and proposed as a candidate target for CAR T cell therapy.

Source 1DOIPubMed

Resources required

Using FAM168B for CAR T development would require target-binding reagents and validation that the protein is accessible on tumor cell surfaces.

Source 1DOIPubMed

What problem it solves

It could provide a new tumor-associated surface target to broaden CAR T cell targeting options.

Source 1DOIPubMed

What it does not solve

The abstract does not show that FAM168B-targeted CAR T cells were built or functionally validated.

Source 1DOIPubMed

Alternatives

The abstract also names the homolog FAM168A/TCRP1 as a related candidate membrane-associated protein.

Source 1DOIPubMed

Evidence Snippets

Here, we identify FAM168B (family with sequence similarity 168 member B, also known as myelin-associated neurite-outgrowth inhibitor, MANI) ... as candidate membrane-associated proteins expressed on cancer cell surfaces.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1identificationsupports2026Source 1DOIPubMed

FAM168B and its homolog FAM168A are identified as candidate membrane-associated proteins expressed on cancer cell surfaces.

Claim 2prospective impactsupports2026Source 1DOIPubMed

Targeting FAM168B could expand the therapeutic repertoire of CAR T cell therapy and support more precise and versatile treatment strategies for diverse cancer types.

Claim 3therapeutic potentialsupports2026Source 1DOIPubMed

The unique characteristics of FAM168B suggest that it has potential as a tumor-specific target for CAR T cell development.